INSMED INC Repayments of Convertible Debt
INSMED INC (INSM) reported Repayments of Convertible Debt of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfConvertibleDebt · last filed 2026-08-06
- INSMED INC repayments of convertible debt for the quarter ending 2025-12-31 was $0.00.
- INSMED INC repayments of convertible debt for the quarter ending 2025-09-30 was $0.00.
- INSMED INC repayments of convertible debt for the quarter ending 2024-12-31 was $0.00.
- INSMED INC repayments of convertible debt for the quarter ending 2024-09-30 was $0.00.
- INSMED INC repayments of convertible debt for fiscal 2025 was $1.97M.
- INSMED INC repayments of convertible debt for fiscal 2024 was $0.00.
- INSMED INC repayments of convertible debt for fiscal 2023 was $0.00.
- INSMED INC repayments of convertible debt for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Repayments of Convertible Debt 3 month | Repayments of Convertible Debt 6 month | Repayments of Convertible Debt 9 month | Repayments of Convertible Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $1.97M 10-K · filed 2026-02-19 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $1.97M 10-Q · filed 2025-10-30 | ||
| 2025-06-30 | $1.97M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $0.00 10-K · filed 2026-02-19 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $0.00 10-Q · filed 2025-10-30 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-07 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-19 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $0.00 derived: sum of 2 quarters · filed 2024-02-22 | $0.00 10-K · filed 2024-02-22 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $0.00 10-Q · filed 2022-10-27 | ||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-04 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $0.00 derived: sum of 2 quarters · filed 2024-02-22 | $225.00M 10-K · filed 2024-02-22 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $225.00M 10-Q · filed 2022-10-27 | ||
| 2021-06-30 | $225.00M 10-Q · filed 2022-08-04 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $0.00 derived: sum of 2 quarters · filed 2023-02-23 | $0.00 10-K · filed 2023-02-23 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $0.00 10-Q · filed 2021-10-28 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-05 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-17 | |||
| 2012-12-31 | $0.00 10-K · filed 2013-03-18 | |||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $0.00 derived: sum of 2 quarters · filed 2013-03-18 | $0.00 10-K · filed 2013-03-18 | |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q/A 6 month · filed 2011-11-09 | $0.00 10-Q · filed 2011-11-09 | ||
| 2011-06-30 | $0.00 10-Q/A · filed 2011-08-08 | |||
| 2010-12-31 | $461.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $461.00K derived: sum of 2 quarters · filed 2013-03-18 | $231.00K 10-K · filed 2013-03-18 | |
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q/A 6 month · filed 2011-11-09 | -$230.00K 10-Q · filed 2011-11-09 | ||
| 2010-06-30 | -$230.00K 10-Q/A · filed 2011-08-08 | |||
| 2009-12-31 | $1.25M 10-K · filed 2012-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |